Chicago, IL (PRWEB) September 19, 2017
Ziegler, a specialty investment bank, is pleased to announce that it has been nominated for three M&A Advisor awards:
- Radiology Alliance in its acquisition by MEDNAX, which Ziegler served as the sole financial advisor, has been named a finalist for Healthcare and Life Sciences Deal of the Year and Corporate/Strategic Deal of the Year categories.
- Med Fusion in its recent sale to Quest Diagnostics, which Ziegler served as the sole financial advisor, has been named a finalist in the >$100mm category for the Healthcare and Life Sciences Deal of the Year and the M&A Deal of the Year awards.
- Oncology Hematology Care (OHC) in its recent partnership with The US Oncology Network (the Network), which Ziegler served as the sole financial advisor, has been named a finalist in the Corporate/Strategic Deal of the Year category.
Ziegler served as the exclusive financial advisor to Radiology Alliance, P.C., and Infinity Management, LLC, on their acquisition by MEDNAX. Andrew Colbert, Managing Director in Ziegler’s Corporate Finance practice stated, “This acquisition was an important strategic move for Radiology Alliance as it aligns them with one of the nation’s largest multispecialty physician groups in the United States.” He continued, “By acquiring Radiology Alliance, MEDNAX is moving into the onsite radiology marketplace by partnering with one of the premier radiology groups in the country. I expect that radiology will a major growth initiative for MEDNAX in the future.”
Grant Chamberlain, Managing Director in Ziegler's Corporate Finance Healthcare practice, commented on the MedFusion transaction, “This transaction was emblematic of the way we at Ziegler help our clients achieve their goals in an increasingly complex healthcare environment. I believe the entity and partnerships we have built between Quest and the original founders will help improve the care of cancer patients.” The transaction allowed Quest Diagnostics to acquire Med Fusion, creating a base in the southwestern United States for providing precision medicine diagnostics to aid cancer treatment and care.
Regarding the Oncology Hematology Care transaction, Mr. Chamberlain, added, “Having spent over 20 years advising physician practices in over 25 transactions in a wide variety of specialties (Anesthesiology, Oncology, Pathology, Radiology, and Primary Care), there is no subspecialty or business model that benefits from the attributes of a Management Company relationship more than Oncology. Oncology practices have a tremendous need to find skilled resources and capital to assist them in navigating the ever-increasing complexities of their business (i.e. evolving reimbursement models, IT infrastructure requirements, capital equipment acquisition needs, drug purchasing, research/clinical trials access, etc.) and US Oncology has perfected a win-win model for their affiliated practices to uniquely meet these requirements.” Ziegler assisted in structuring and modeling the management services agreement, negotiating key terms of the partnership, presenting the partnership to OHC’s shareholders, and facilitating due diligence.
The winners for M&A Deal of the Year, Restructuring Deal of the Year, Cross-Border Deal of the Year, Corporate/Strategic Acquisition of the Year, Deal Financing of the Year, Sector Deals of the Year, Firms of the Year, M&A Product/Service of the Year and M&A Professionals categories will be announced at the 16th Annual M&A Advisor Awards Gala on Monday, November 13th at the Metropolitan Club in New York.
“Since the inception of the M&A Advisor Awards in 2002, we have been recognizing the leading dealmakers, firms and transactions. And each year we celebrate the creativity, perseverance and ingenuity of our industry’s professionals”, says David Fergusson, President and Co-Chief Executive Officer of The M&A Advisor. “While our industry has undergone significant transformation since our first awards were presented 15 years ago, we are convinced, more than ever before, that M&A is a driving force of the economy. It is truly an honor for our firm to be able to recognize the contribution that the 2017 award finalists have made.”
For a detailed list of all of the Award Finalists for the 16th Annual M&A Advisor Awards, please click here.
For more information about Ziegler, please visit us at http://www.ziegler.com.
About The M&A Advisor:
The M&A Advisor was founded in 1998 to offer insights and intelligence on mergers and acquisitions through the industry’s leading publication. Today, the firm is recognized as the world’s premier “think tank” and leadership organization for M&A, restructuring and financing professionals, providing a range of integrated services including: M&A Advisor Forums and Summits; M&A Advisor Market Intelligence; M&A.TV.; M&A Advisor Live; M&A Advisor Awards; and M&A Advisor Connects. For additional information about The M&A Advisor’s leadership services visit http://www.maadvisor.com
Ziegler is a privately held investment bank, capital markets, wealth management and proprietary investments firm, celebrating its 115th anniversary this year. Ziegler is ranked No. 1 in the country in healthcare/senior living underwriters by issuance and No. 4 by par amount (Thomson Reuters, 2016), and is ranked in the top 20 municipal underwriters in the country by volume (Bloomberg, 2016). Specializing in the healthcare, senior living, education and religion sectors, as well as general municipal and structured finance enables Ziegler to generate a positive impact on the communities it serves. Headquartered in Chicago with regional and branch offices throughout the United States, Ziegler provides its clients with capital raising, strategic advisory services, equity and fixed income sales & trading, wealth management and research. To learn more, visit http://www.ziegler.com.
Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client’s experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.
# # #